Sugi Predict

Sugi Predict / Compounds / SCHEMBL3135239

SCHEMBL3135239

SCHEMBL3135239

COc1cc(C(=O)O)ccc1NC(=O)c1cc(F)ccc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGL P06737 6/20 0.69
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ LMNA P02545 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ AVPR2 P30518 2/20 0.55
▸ AVPR1A P37288 2/20 0.55
▸ POLB P06746 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.52
▸ TAS1R3 Q7RTX0 1/20 0.52
▸ TAS1R1 Q7RTX1 1/20 0.52
▸ TAS1R2 Q8TE23 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3138705 0.91 PYGL (0.57) PYGLSMN1; SMN2KDM4EAVPR2AVPR1A
SCHEMBL3134272 0.91 ALDH1A1 (0.58) PYGLSMN1; SMN2KDM4EAVPR2AVPR1A
SCHEMBL20601617 0.91 PYGL (0.83) PYGLSMN1; SMN2KDM4ELMNARAB9A
SCHEMBL22871318 0.87 PYGL (0.61) PYGLSMN1; SMN2KDM4ELMNARAB9A
SCHEMBL22871266 0.87 PYGL (0.64) PYGLSMN1; SMN2KDM4ELMNARAB9A
SCHEMBL20601611 0.87 PYGL (0.61) PYGLSMN1; SMN2LMNARAB9APOLB
SCHEMBL31585962 0.87 PYGL (0.61) PYGLSMN1; SMN2LMNARAB9APOLB
SCHEMBL20602308 0.85 PYGL (0.65) PYGLSMN1; SMN2KDM4ELMNARAB9A
SCHEMBL22871358 0.84 TAS1R3 (0.53) PYGLSMN1; SMN2LMNARAB9AAVPR2
SCHEMBL20601662 0.84 PYGL (0.82) PYGLSMN1; SMN2KDM4ELMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120025312-A Benzazepine derivatives 大塚制药株式会社 2025-05-23 — — CN disclosed
US-20250051310-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-02-13 — — US disclosed
EP-4056557-B1 BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS OTSUKA PHARMA CO LTD (JP) 2023-11-22 — — EP disclosed
US-20230265073-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-08-24 — — US disclosed
US-11673878-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-06-13 — — US disclosed
US-20210078976-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-03-18 — — US disclosed
US-10889570-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 — — US disclosed
EP-3645513-A1 BENZAZEPINE DERIVATIVES Otsuka Pharmaceutical Co., Ltd. (JP) 2020-05-06 — — EP disclosed
CN-110891939-A Benzazepine derivatives 大塚制药株式会社 2020-03-17 — — CN disclosed
WO-2019004421-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-03 — — WO disclosed
EP-1633721-A1 PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-15 — — EP disclosed
EP-1633719-A2 SUBSTITUTED SPIROBENZAZEPINES JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-15 — — EP disclosed
WO-2005037795-A2 SUBSTITUTED SPIROBENZAZEPINES JANSSEN PHARMACEUTICA N.V. (BE) 2005-04-28 — — WO disclosed
WO-2005000819-A1 PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2005-01-06 — — WO disclosed
US-20040266752-A1 Substituted spirobenzazepines JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-30 — — US disclosed
US-20040266752-A1 Substituted spirobenzazepines JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-30 — — US disclosed
US-20040266752-A1 Substituted spirobenzazepines JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-30 — — US disclosed
US-20040259857-A1 Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2004-12-23 — — US disclosed
US-20040259857-A1 Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2004-12-23 — — US disclosed
US-20040259857-A1 Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2004-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266752-A1 Substituted spirobenzazepines AVPR2, AVPR1B, AVPR1A PYGL 439/4885SMN1; SMN2 2310/4885KDM4E 4036/4885
US-20040259857-A1 Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives REN, AVPR1B, WNK1 PYGL 3898/4885SMN1; SMN2 4333/4885KDM4E 2800/4885
US-20210078976-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B PYGL 4868/4885SMN1; SMN2 4356/4885KDM4E 1707/4885
US-20230265073-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B PYGL 4868/4885SMN1; SMN2 4356/4885KDM4E 1707/4885
US-11673878-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B PYGL 4868/4885SMN1; SMN2 4356/4885KDM4E 1707/4885
US-20250051310-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B PYGL 4841/4885SMN1; SMN2 4154/4885KDM4E 1739/4885
US-10889570-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B PYGL 4868/4885SMN1; SMN2 4356/4885KDM4E 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.